Efficacy of resistance training for the prevention of cognitive decline.

Not Applicable

Completed

• Conditions: Cognitive decline; Mental Health - Other mental health disorders; Neurological - Other neurological disorders

• Registration Number: ACTRN12616000690459
• Lead Sponsor: Murdoch University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Considered low to moderate risk for moderate intensity exercise as per Exercise and Sports Science Australia risk stratification. Participants should be considered healthy.

Exclusion Criteria

1.Have more than two risk factors in the Exercise and Sports Science Australia pre-exercise screening tool questionnaire
2.Present with chronic musculoskeletal disease or injury
3.Show signs of mild cognitive impairment or dementia
4.Are a current smoker
5.Are currently taking selective serotonin reuptake inhibitor medication (Citalopram [Celexa], Escitalopram [Lexapro], Fluoxetine [Prozac], Paroxetine [Paxil, Pexeva] or Sertraline [Zoloft])
6.Have a history of neurological disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function will be assessed using the CogState battery plus Rey Complex Figure, Rey Auditory Verbal Learning Test, Controlled Oral Word Association Test, Category Fluency, Trail Making Test Parts A & B, Montreal Cognitive Assessment, Digit Span and Digit Symbol Substitution Test.[Baseline and 12 weeks.]

Secondary Outcome Measures

Name	Time	Method
Frontal lobe tissue oxygenation via near-infrared spectroscopy[Baseline and 12 weeks.];Brain-derived neurotrophic factor by serum ELISA.[Baseline and 12 weeks.];Insulin-like growth factor 1 by serum ELISA.[Baseline and 12 weeks.];Vascular endothelial growth factor by plasma ELISA.[Baseline and 12 weeks.];Endothelial nitric oxide synthase by plasma ELISA.[Baseline and 12 weeks.];Body composition via dual-energy x-ray absorptiometry[Baseline, 6 weeks, 12 weeks.]